ITM Radiopharma’s Phase III trial of its targeted radiotherapeutic for patients with Grade 1 or 2 gastroenteropancreatic ...

The FDA has approved Cabometyx for some patients 12 years old and older with previously treated neuroendocrine tumors.

in patients with grade 1 or 2 gastroenteropancreatic neuroendocrine tumors in the phase III COMPETE trial, ITM Isotope ...

The drug is being developed for gastroenteropancreatic neuroendocrine tumor, pancreatic net, neuroendocrine tumors, extensive stage small cell lung cancer (ES-SCLC), and other tumors. Currently ...

well-differentiated pancreatic neuroendocrine tumors (pNET) and extrapancreatic NET (epNET). Specifically, the approval is for those with unresectable, locally advanced, or metastatic pNET and ...

Based on the phase 3 CABINET trial, the FDA approved Cabometyx for some patients with previously treated neuroendocrine ...

NSCLC = non-small cell lung cancer; CUP = carcinoma of unknown primary; CCC = cholangiocarcinoma; GEP-NET= Gastroenteropancreatic neuroendocrine tumor. Image created with contributions from ...

Currently, her areas of focus include the development of novel theranostic agents for pancreatic cancers and understanding the role of Notch signaling in gastroenteropancreatic neuroendocrine tumors.

The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.